Immunomedics, Inc. (IMMU) Q1 2020 Earnings Conference Call May 6, 2020 5:00 PM ET
Company Participants
Chau Cheng – Senior Director-Investor Relations
Behzad Aghazadeh – Executive Chairman
Usama Malik – Chief Financial Officer and Chief Business Officer
Brendan Delaney – Chief Commercial Officer
Conference Call Participants
Michael Schmidt – Guggenheim
Peter Lawson – Barclays
Phil Nadeau – Cowen & Company
Joe Catanzaro – Piper Sandler
Nick Abbott – Wells Fargo Securities
Roger Song – Jefferies
Vikram Purohit – Morgan Stanley
Operator
Good afternoon, ladies and gentlemen, thank you for standing by. As a reminder, this call is being recorded, today is Wednesday, May 6, 2020.
At this time, I would like to turn the conference over to Chau Cheng, Senior Director of Investor Relations of Immunomedics.
Chau Cheng
Thank you, Jimmy. Before we begin, I’d like to remind everyone that during this call, we will be making forward-looking statements made pursuant to the Private Securities Litigation Reform Act of 1995. Such statements may involve significant risks and uncertainties and therefore actual results could differ materially from those expressed or implied on this call. Factors that could cause such a difference include the uncertainty associated with pharmaceutical development and regulatory approval process as well as difficulty in forecasting sales, revenues and expenses.
More information about the risks and uncertainties faced by Immunomedics. Immunomedics is contained with the caption Risk Factors included in the company's periodic reports filed with the Securities and Exchange Commission, including the company's Annual Report on Form 10-K for the year ended December 31, 2019.
With us on the call today with prepared remarks are Dr. Behzad Aghazadeh, Executive Chairman; and Usama Malik, our Chief Financial Officer and Chief Business Officer. Also on the call for Q&A are Harout Semerjian, President and Chief Executive Officer and Brendan Delaney, Chief Commercial Officer. Following the prepared remarks, we will
- Read more current IMMU analysis and news
- View all earnings call transcripts